Skip to main content
Obstructive Hypertrophic CardiomyopathyDrug

What this study is

This registry evaluates patient characteristics, real-world treatment patterns, and short- and long-term outcomes in a population of patients in the United States and Europe with symptomatic obstructive hypertrophic cardiomyopathy (HCM) who are receiving mavacamten, receiving other treatment for obstructive HCM, or not receiving treatment for obstructive HCM due to intolerance or failure of prior treatment.

United States Sub-Study: The purpose of this study is to evaluate the safety of mavacamten in patients with symptomatic obstructive HCM in the real-world setting.

Europe Sub-Study: The purpose of this study is to evaluate the effectiveness and safety of mavacamten in patients with symptomatic obstructive HCM in the real-world setting.

What's being tested

  • Mavacamten

    Intervention · DRUG

    As per product label

  • Non-mavacamten symptomatic oHCM therapy

    Intervention · DRUG

    Including Beta-blocker (BB), non-dihydropyridine (non-DHP) calcium channel blocker (CCB) and/or disopyramide as per product label

Study details

Official title
Deliver Insights in Hypertrophic Cardiomyopathy and Observational Outcomes in Real World: United States and European Prospective Registry Study
Sponsor
Bristol-Myers Squibb
Conditions
Obstructive Hypertrophic Cardiomyopathy
Enrolling
1,700 people
Starts
2022-08-16
Est. completion
2029-08-17
Record
View on ClinicalTrials.gov ↗